Prandin FDA Alerts
The FDA Alert(s) below may be specifically about Prandin or relate to a group or class of drugs which include Prandin (repaglinide).
MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com. Following is a list of possible medication recalls, market withdrawals, alerts and warnings. For the latest FDA MedWatch alerts, go here.
Recent FDA Alert(s) for repaglinide
Prandin (repaglinide)
Sep 29, 2003
Audience: Endocrinologists, pharmacists and other healthcare providers
Novo Nordisk and FDA revised the PRECAUTIONS/Drug Interaction section of the prescribing information to inform healthcare professionals of a drug-drug interaction between repaglinide (PRANDIN), a short-acting insulin secretagogue, and gemfibrozil (Lopid) a lipid-lowering agent used to treat dyslipidemia.A study that evaluated the co-administration of gemfibrozil with PRANDIN in healthy subjects found a significant increase in repaglinide blood levels. Concomitant use may result in enhanced and prolonged blood glucose-lowering effects of repaglinide. For patients already on PRANDIN and gemfibrozil, blood glucose levels should be monitored and PRANDIN dose adjustment may be needed.
[Sept, 2003 Letter - Novo Nordisk] PDF Format
[August, 2003 Revised, highlighted label - Novo Nordisk] PDF Format
